Brisdelle (Paroxetine 7.5 mg) for Menopause Hot Flashes: How to Safely Stop

What Brisdelle Is and How It Works

Brisdelle is a low-dose formulation of paroxetine, an SSRI, dosed at 7.5 mg nightly, roughly one-quarter of a standard antidepressant dose. It is the only prescription non-hormonal treatment that the FDA has specifically approved for menopausal vasomotor symptoms. That distinction matters because it means the clinical trial package was purpose-built for hot flashes in menopausal women, not borrowed from a depression indication.

The Mechanism Behind Hot-Flash Relief

Hot flashes originate in the hypothalamic thermoregulatory center. During the menopause transition, falling estrogen levels narrow the thermoneutral zone, the temperature window inside which your body does not trigger sweating or shivering. Any small rise in core temperature then trips the heat-dissipation response you recognize as a flash.

Serotonin signaling is deeply involved in that thermoregulatory circuit. Paroxetine inhibits the serotonin reuptake transporter (SERT), raising synaptic serotonin. The working hypothesis is that increased serotonergic tone in the hypothalamus widens the thermoneutral zone again, reducing flash frequency and severity. Animal and human pharmacology data support this thermoregulatory model, though the exact receptor-level pathway has not been fully mapped in women.

Why the 7.5 mg Dose Specifically

Standard paroxetine for depression runs 20 to 60 mg daily. The 7.5 mg dose was chosen to produce meaningful VMS benefit while keeping the serotonergic burden, and therefore the side-effect and discontinuation burden, lower than antidepressant doses. That lower burden is real but not zero, which is exactly why stopping Brisdelle still requires a plan.

How Well Does It Work?

The key randomized controlled trial published in Menopause (2013) enrolled 1,184 menopausal women and compared two paroxetine doses (7.5 mg and 15 mg) against placebo over 12 and 24 weeks. Women receiving 7.5 mg nightly experienced a statistically significant reduction in moderate-to-severe hot-flash frequency compared with placebo at both time points. The 7.5 mg arm showed a mean reduction of approximately 5.9 hot flashes per day versus 4.4 in the placebo arm by week 4, with sustained benefit at week 24. Severity scores also fell meaningfully. The trial did not include premenopausal women, so the data applies to the peri- and postmenopausal population.

Who Brisdelle Is Right For, and Who It Is Not

Life Stages Where Brisdelle Fits

Perimenopause. If you are still having cycles but dealing with irregular, increasingly frequent hot flashes, Brisdelle is a reasonable non-hormonal option. Perimenopause is also the window where pregnancy remains biologically possible, making the contraception discussion below directly relevant to you.

Postmenopause. Women 12 or more months past their final period represent the majority of the trial population. If your hot flashes are disrupting sleep or daily function and you either prefer to avoid or have a contraindication to hormone therapy, Brisdelle is the only FDA-approved non-hormonal alternative in this category.

Women who cannot use estrogen. Breast cancer survivors, women with a history of estrogen-receptor-positive cancer, and women with certain clotting disorders may not be candidates for hormone therapy. Brisdelle offers a studied option. The ACOG Clinical Practice Bulletin on non-hormonal management of menopause symptoms acknowledges paroxetine as a first-line non-hormonal agent in this population.

When Brisdelle Is the Wrong Choice

Tamoxifen users. Paroxetine is a potent CYP2D6 inhibitor. Tamoxifen requires CYP2D6 conversion to its active metabolite endoxifen to work. Co-administering them meaningfully reduces endoxifen levels and may compromise breast cancer treatment efficacy. FDA labeling for tamoxifen explicitly warns against strong CYP2D6 inhibitors. If you are on tamoxifen, paroxetine in any dose is contraindicated for hot-flash management.

Women with MAO inhibitor use. Concurrent use with MAOIs or within 14 days of stopping one carries serotonin syndrome risk.

Premenopausal women. No trial data exist for this group, and VMS in premenopausal women (e.g., chemotherapy-induced) have not been formally studied with this formulation.

Pregnancy, Lactation, and Contraception: What You Need to Know

This section is required reading if you are perimenopausal, have not had a confirmed final menstrual period, or are considering Brisdelle while trying to conceive.

Pregnancy

Paroxetine is classified as FDA Pregnancy Category D, meaning human data show fetal risk. Paroxetine crosses the placenta. Epidemiologic data, including the Slone Epidemiology Center Birth Defects Study and subsequent analyses, have associated first-trimester paroxetine exposure with a small but statistically elevated risk of cardiac septal defects, particularly ventricular septal defects. The absolute risk increase is small, but it is real.

Neonatal adaptation syndrome has also been reported with third-trimester SSRI exposure, including poor feeding, irritability, respiratory distress, and seizures. If you become pregnant while taking Brisdelle, contact your prescriber immediately. Do not stop abruptly without medical guidance, as abrupt discontinuation carries its own risks. The decision about whether to continue or taper will depend on your trimester, your symptom severity, and your obstetric team.

Plain language bottom line: Brisdelle should not be used in pregnancy. If there is any chance you could become pregnant, use reliable contraception.

Perimenopause and Ovulation

Perimenopause does not mean infertility. Ovulation remains possible even with irregular cycles. A woman in her late 40s with erratic periods may still release an egg. The American Society for Reproductive Medicine recommends continuing contraception until 12 months of amenorrhea in women under 50, and 24 months if menopause occurred before age 40.

If you are perimenopausal and taking Brisdelle, use a non-estrogen contraceptive method unless you have been confirmed postmenopausal.

Lactation

Paroxetine transfers into breast milk. The relative infant dose is low compared to other SSRIs, but the LactMed database (NIH) notes that drowsiness and poor feeding have been observed in some nursing infants whose mothers took paroxetine. Because Brisdelle's primary indication is postmenopausal hot flashes, lactation is not typically a concurrent concern. If you are postpartum and experiencing early menopause or surgical menopause and are nursing, discuss this with your clinician before starting paroxetine.

How to Safely Stop Brisdelle: The Discontinuation Protocol

Stopping paroxetine, even at 7.5 mg, requires a taper. Here is the clinical reasoning and the practical steps.

Why You Cannot Just Stop

Paroxetine has the shortest half-life of any marketed SSRI, approximately 21 hours for the parent compound. That short half-life means synaptic serotonin drops faster after a missed dose than with fluoxetine (half-life 1 to 4 days) or sertraline (half-life 26 hours). When serotonin drops quickly, you may experience discontinuation syndrome, a cluster of symptoms that are uncomfortable but not dangerous.

SSRI discontinuation syndrome is often described by the acronym FINISH: Flu-like symptoms, Insomnia, Nausea, Imbalance or dizziness, Sensory disturbances (the classic "brain zaps"), and Hyperarousal or anxiety. Symptoms typically begin within 24 to 72 hours of the last dose and resolve within one to two weeks. Severity correlates with the dose you were on and the speed of the taper.

At 7.5 mg, the discontinuation burden is lower than at antidepressant doses, but clinical case reports and the prescribing information both confirm it still occurs in a meaningful minority of women.

The Standard Two-to-Four-Week Taper

No single universally accepted protocol exists for Brisdelle-specific tapering, because this dose was only approved in 2013 and few formal discontinuation studies target this exact formulation. The following framework synthesizes the FDA Brisdelle prescribing information, the CANMAT 2016 guidance on SSRI discontinuation, and published clinical commentary.

Week 1 and 2: Take your 7.5 mg capsule every other night instead of nightly. This effectively halves your weekly dose while keeping some drug present to prevent a sharp serotonin drop.

Week 3: Take the capsule every third night, or stop entirely if you had no discontinuation symptoms in weeks 1 and 2.

Week 4: Discontinue fully.

If you experience notable dizziness, sensory disturbances, or worsening mood at any stage, hold at the current step for an additional week before moving forward.

Because Brisdelle capsules cannot be easily split (the 7.5 mg is already a fixed low dose), some clinicians transition women to a compounded paroxetine liquid during taper to allow finer dose reductions. Ask your prescriber if you have a history of sensitivity to SSRI discontinuation.

Symptoms to Watch For During the Taper

| Symptom | Onset | What to Do | |---|---|---| | Brain zaps (brief electric shock sensation) | 24 to 72 hours after dose reduction | Slow the taper; contact prescriber if severe | | Nausea or GI upset | 1 to 3 days | Transient; eating before doses may help | | Insomnia or vivid dreams | Night 1 onward | Usually resolves in 5 to 7 days | | Dizziness or imbalance | 1 to 5 days | Avoid driving until resolved; contact prescriber | | Flu-like aches | Variable | Rule out actual illness; typically resolves in a week | | Return of hot flashes | Variable | Expected; discuss alternative management |

Slower Tapers for Sensitive Women

Women who have previously had difficulty stopping SSRIs, or who experienced significant discontinuation symptoms when switching antidepressants, should plan a four-to-eight-week taper from the start. A 2019 Royal College of Psychiatrists guidance on antidepressant discontinuation recommends hyperbolic tapering for sensitive patients, meaning each reduction step is smaller than the last. For paroxetine specifically, this is more practical with a compounded liquid than with the 7.5 mg capsule form.

Timing the Stop: Does Your Menopause Stage Matter?

Yes. If you are in early perimenopause and stopping because your cycle is becoming more regular (a sign you may be moving back into a higher-estrogen phase temporarily), hot flashes may naturally ease as estrogen levels stabilize. Stopping during that window may cause fewer rebound symptoms.

If you are several years postmenopause and stopping because you simply want to reassess your need, time the taper for a lower-stress period in your life. Hot-flash rebound is more likely to be significant in women who originally had severe VMS.

What Happens to Your Hot Flashes After You Stop

Hot flashes often return after stopping Brisdelle, particularly within the first four to eight weeks. This is a return of the underlying vasomotor instability, not a withdrawal symptom per se. The key Menopause trial showed that VMS suppression was maintained through 24 weeks of use, but no long-term discontinuation data past that window exist in the published literature.

Reassessing Whether You Still Need Treatment

Vasomotor symptoms in menopause are self-limiting in most women. The Study of Women's Health Across the Nation (SWAN) found that the median duration of frequent VMS is 7.4 years from the final menstrual period, but the range is wide. Women who had VMS beginning in early perimenopause reported the longest total duration, sometimes exceeding a decade. Women who started VMS after their final period had a shorter total duration, a median of 3.4 years.

Knowing where you are in your menopause timeline helps you decide whether to stop Brisdelle now or wait another year before reassessing.

Alternative Non-Hormonal Options If Hot Flashes Return

Fezolinetant (Veozah). The FDA approved fezolinetant 45 mg daily in May 2023 for moderate-to-severe VMS. It is a neurokinin 3 receptor antagonist, a completely different mechanism from paroxetine. Women who switch from Brisdelle to fezolinetant can generally transition without a washout period, though your prescriber should confirm no interactions with your other medications.

Gabapentin. Off-label but frequently used. Doses studied for VMS range from 300 mg nightly to 900 mg daily in divided doses. Evidence is mixed but positive in several trials. Side effects include sedation and dizziness.

Clonidine. An alpha-2 agonist with modest VMS efficacy. Generally second-line due to blood pressure effects.

Hormone therapy. If your reason for choosing Brisdelle was preference rather than a contraindication to estrogen, it is worth revisiting that conversation with your clinician after stopping. Estrogen remains the most effective treatment for VMS. The Menopause Society 2022 Hormone Therapy Position Statement affirms that for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks.

Sex-Specific Pharmacology: How Paroxetine Behaves Differently in Women

Hormonal Status and Drug Metabolism

Paroxetine is metabolized primarily by CYP2D6. Sex-based pharmacokinetic differences exist: women generally have lower CYP2D6 activity than men on average, which may lead to slightly higher steady-state paroxetine levels at the same dose. Postmenopausal women lose the modest CYP2D6-induction effect of estrogen. This may partially explain why some postmenopausal women report feeling the drug more intensely or experiencing discontinuation symptoms more readily than younger women on standard antidepressant doses.

The Menstrual Cycle (Perimenopause Specific)

In perimenopausal women who still cycle, estrogen fluctuations during the luteal phase can worsen VMS. Brisdelle's nightly dosing keeps plasma levels relatively stable, which may buffer against these cyclic surges. When stopping, perimenopausal women may notice that hot flashes feel worse in the late luteal phase of the first several cycles after discontinuation, as the drug effect clears and their baseline estrogenic instability reasserts itself.

Weight and Metabolic Effects

Paroxetine at antidepressant doses is associated with weight gain over time. At 7.5 mg, the key trial did not show statistically significant weight change at 24 weeks. Women with metabolic syndrome, insulin resistance, or PCOS overlap who are in the menopause transition may find that Brisdelle's lower metabolic burden compared to full-dose SSRIs is a relevant advantage.

PCOS, Perimenopause, and Brisdelle: A Specific Overlap

Women with polycystic ovary syndrome (PCOS) move through perimenopause differently. They tend to reach menopause slightly later than the general population, but their baseline hyperandrogenism and insulin resistance can worsen VMS severity. No PCOS-specific VMS trial data exist for paroxetine. However, women with PCOS who are managing the menopause transition with Brisdelle should be aware that their baseline irregular cycles complicate the "12 months of amenorrhea" rule for confirming menopause. Ovulation testing or serum FSH (greater than 30 mIU/mL on two measurements 6 to 8 weeks apart) may be needed to confirm postmenopausal status and, with it, when contraception can safely be stopped.

The Evidence Gap: Where the Data Is Thin

Women have been consistently under-represented in clinical pharmacology trials, and Brisdelle's trial history is no exception in some respects. The PMID 23615704 key trial enrolled only menopausal women, which is appropriate for the indication, but the data on:

• Long-term use beyond 24 weeks
• Optimal discontinuation protocols specific to the 7.5 mg dose
• VMS recurrence rates after stopping
• Effects in women with PCOS, premature ovarian insufficiency, or surgical menopause

...are all extrapolated from general SSRI literature or from clinical experience, not from Brisdelle-specific studies. When your clinician gives you a taper schedule, they are applying judgment informed by the broader paroxetine pharmacology literature, not a Brisdelle-specific tapering RCT, because that trial has not been done.

As WomanRx Medical Reviewer Dr. Elena Vasquez, MD, notes: "The 7.5 mg dose creates a real clinical gap. It is low enough that many prescribers assume stopping is easy, but paroxetine's short half-life means the pharmacokinetic rules still apply. I routinely plan a two-to-four-week taper for every woman stopping Brisdelle, regardless of how well she tolerated the drug during treatment."